The LTC Innovation Blog

Medication regimen reviews shouldn't just check a compliance box. They should strengthen your business. Medication regimen reviews (MRRs) are one of the most important clinical services a long-term care pharmacy provides. Yet many pharmacies still approach MRR as an operational obligation rather than a strategic advantage. It is a proven area of opportunity to strengthen facility relationships, demonstrate clinical expertise, and provide differentiation in an increasingly competitive market, all while reducing costs in the long term. As labor pressures continue to rise and facilities expect more from their pharmacy partners, it's worth asking a different question: Is your medication regimen review process helping your pharmacy grow, or simply helping it stay compliant?

For LTC pharmacies who need to coordinate closely with care givers at the facilities they dispense to, interoperability with eMAR and EHR systems used at the point of care have become paramount in daily operations. What used to require manual faxing, phone calls, filing, and hand keying transcription has been transformed in the digital healthcare era. Through electronic integrations pharmacy teams are able to operate more lean operations with staff spending less time on manual documentation. However, with the shift to electronic system integration being the current base-line for operations a modern pharmacy, the cost of poor integrations in pharmacy systems has become harder to absorb as prescription volumes grow and margins compress.

The sale of Omnicare's LTC pharmacy business is more than another healthcare transaction — it's a signal that the economic and operational realities facing long-term care (LTC) pharmacy are evolving in ways that affect every type of provider in the market, large or small. On May 13, 2026, the U.S. Bankruptcy Court for the Northern District of Texas approved the $250 million sale of Omnicare — a subsidiary of CVS Health — to GenieRx Holdings LLC, a joint partnership between private investment firm Milrose Capital LLC and healthcare investment and management firm Integro Asset Management LLC, operating as Integro Healthcare Services. The transaction is expected to close later in 2026, pending regulatory approval, with Omnicare continuing to serve its clients through the transition period.